Ignite Creation Date:
2024-05-06 @ 7:20 PM
Last Modification Date:
2024-10-26 @ 3:05 PM
Study NCT ID:
NCT05977673
Status:
RECRUITING
Last Update Posted:
2023-11-24
First Post:
2023-07-28
Brief Title:
Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy
Sponsor:
Fondazione Italiana Linfomi - ETS
Organization:
Fondazione Italiana Linfomi - ETS
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-12
Start Date Type:
ESTIMATED
Primary Completion Date:
2027-04
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-04
Completion Date Type:
ESTIMATED
First Submit Date:
2023-07-28
First Submit QC Date:
August 3 2023
Study First Post Date:
2023-08-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-07-18
Last Update Post Date:
2023-11-24
Last Update Post Date Type:
ACTUAL